Latest News & Updates

Breaking News

6 minutes ago
Simantini Singh Deo

Tempest Therapeutics, Inc. Reports Strong New Clinical Results For TPST-2003, Its CD19/BCMA Dual-Targeting CAR-T Therapy, In Ongoing REDEEM-1 Phase 1/2a Study

Zydus Lifesciences Limited Set To Launch Semaglutide Injection In India As Patent Expires, Introducing New Adjustable Single-Pen Device Under SEMAGLYN, MASHEMA And ALTERME

Simantini Singh Deo

INTERPHEX WEEK TOKYO to Expand Its 2026 Showcase as Japan’s Largest Pharma and Biotech Gathering

Team Pharma Now

Paratek Advances NUZYRA For Pulmonary Anthrax With Positive Animal Rule Data And Additional BARDA Procurement

Vaibhavi M.

Aktis Oncology Receives FDA Fast Track Designation For AKY-1189 In Metastatic Urothelial Cancer

Vaibhavi M.

Other trending news you may like to read

Tempest Therapeutics, Inc. Reports Strong New Clinical Results For TPST-2003, Its CD19/BCMA Dual-Targeting CAR-T Therapy, In Ongoing REDEEM-1 Phase 1/2a Study

Tempest Therapeutics, Inc. reports 100% response rate for TPST-2003 in REDEEM-1 study.

Simantini Singh Deo

Zydus Lifesciences Limited Set To Launch Semaglutide Injection In India As Patent Expires, Introducing New Adjustable Single-Pen Device Under SEMAGLYN, MASHEMA And ALTERME

Zydus Lifesciences Limited to launch semaglutide in India post-patent with new adjustable single-pen device.

Simantini Singh Deo

INTERPHEX WEEK TOKYO to Expand Its 2026 Showcase as Japan’s Largest Pharma and Biotech Gathering

INTERPHEX WEEK TOKYO 2026 returns May 20–22 with 950+ exhibitors, uniting pharma/biotech innovations, CMO/CDMO expo, and regenerative medicine showcase.

Team Pharma Now

Paratek Advances NUZYRA For Pulmonary Anthrax With Positive Animal Rule Data And Additional BARDA Procurement

Paratek reports positive Animal Rule data for NUZYRA in pulmonary anthrax, triggering additional BARDA procurement.

Vaibhavi M.